DUE模式在评价胰岛素临床应用中的研究与实证

摘 要 目的：建立精蛋白生物合成人胰岛素注射液(预混30R)的药物利用评价（DUE)标准,为合理使用该药提供参考。方法: 参照国内外文献及糖尿病治疗的权威指南，结合德尔菲专家咨询法建立药物利用评价标准，经评价、干预、再评价的过程得出精蛋白生物合成人胰岛素注射液（预混30R）的最终DUE标准。结果: 精蛋白生物合成人胰岛素注射液(预混30R)DUE 标准包括用药指征、用药过程、用药结果三个部分，具有临床可行性。结论:DUE模式对规范临床药物的合理使用具有一定的促进作用，可为相关医疗机构开展DUE工作提供参考。

Research and Demonstration of DUE Mode in the Clinical Utilization Evaluation of Insulin

ABSTRACT Objective: To establish the drug utilization evaluation (DUE) criteria for isophane protamine biosyntheti (30R) to provide reference for the rational drug use. Methods: Referred to the domestic and foreign literatures and the authorized guidelines for diabetes treatment, and combined with the Delphi expert consultation method, the drug utilization evaluation criteria was established, and after the evaluation, intervention and revaluation, the final criteria were determined. Results: The drug utilization evaluation criteria for isophane protamine biosyntheti (30R) contained three parts, including medication indications, medication process and medication results, which showed the clinical feasibility. Conclusion:The established DUE criteria for isophane protamine biosyntheti (30R) can not only be applied in the drug utilization evaluation, but also provide reference for the DUE in medical institutions.